Clinical performance of a point-of-care assay for measurement of presepsin in patients with bacteremia
© Fukui et al.; licensee BioMed Central Ltd. 2013
Published: 5 November 2013
The soluble CD14 subtype (sCD14-ST: renamed presepsin), which is approximately 13 kDa, has been identified as a protein whose levels increase specifically in the blood of sepsis patients. In this study, we evaluated the clinical performance of a point-of-care assay for measurement of presepsin in admitted sepsis patients.
Materials and methods
We obtained 43 cases with blood culture test-positive from patients admitted to our hospital and compared presepsin levels with procalcitonin (PCT), CRP and white blood cell count.
Positive ratios of presepsin levels of patients with Gram-negative bacterial infection, Gram-positive bacterial infection and fungal infection were higher than those of PCT. When 43 cases were divided into four groups (sepsis, severe sepsis, septic shock and infection groups), presepsin levels were only significantly different between sepsis/infection group and severe sepsis group (P < 0.05). Presepsin levels reflected the blood culture test and sepsis severity more than other biomarkers.
This assay has sufficient clinical performance in patients admitted to the hospital in addition to the emergency room and ICU.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.